HIGHLIGHTS
- who: Michele Provenzano et al. from the (UNIVERSITY) have published the research: Precision Nephrology in Patients with Diabetes and Chronic Kidney Disease, in the Journal: (JOURNAL)
- what: Several trials have been carried out in the past two decades with the important aim of reducing this residual cardiorenal risk in DKD patients as strongly as possible. This study showed that treatment with dulaglutide, at both doses of 0.75 mg and 1.5 mg per day, was associated with a slower eGFR decline as compared to insulin glargine. This approach has been shown to be clinical . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.